Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs

A Sánchez–Fueyo, TB Strom - Gastroenterology, 2011 - Elsevier
Gastroenterology, 2011Elsevier
Transplantation of organs between genetically different individuals of the same species
causes a T cell–mediated immune response that, if left unchecked, results in rejection and
graft destruction. The potency of the alloimmune response is determined by the antigenic
disparity that usually exists between donors and recipients and by intragraft expression of
proinflammatory cytokines in the early period after transplantation. Studies in animal models
have identified many molecules that, when targeted, inhibit T-cell activation. In addition …
Transplantation of organs between genetically different individuals of the same species causes a T cell–mediated immune response that, if left unchecked, results in rejection and graft destruction. The potency of the alloimmune response is determined by the antigenic disparity that usually exists between donors and recipients and by intragraft expression of proinflammatory cytokines in the early period after transplantation. Studies in animal models have identified many molecules that, when targeted, inhibit T-cell activation. In addition, some of these studies have shown that certain immunologic interventions induce transplantation tolerance, a state in which the allograft is specifically accepted without the need for chronic immunosuppression. Tolerance is an important aspect of liver transplantation, because livers have a unique microenvironment that promotes tolerance rather than immunity. In contrast to the progress achieved in inducing tolerance in animal models, patients who receive transplanted organs still require nonspecific immunosuppressant drugs. The development of calcineurin inhibitors has reduced the acute rejection rate and improved short-term, but not long-term, graft survival. However, long-term use of immunosuppressive drugs leads to nephrotoxicity and metabolic disorders, as well as manifestations of overimmunosuppression such as opportunistic infections and cancers. The status of pharmacologic immunosuppression in the clinic is therefore not ideal. We review recently developed therapeutic strategies to promote tolerance to transplanted livers and other organs and diagnostic tools that might be used to identify patients most likely to accept or reject allografts.
Elsevier